We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Siemens Healthineers and Carna Health Partner to Advance Kidney Care Innovation

By LabMedica International staff writers
Posted on 28 Aug 2025

Chronic kidney disease (CKD) is a growing global health challenge, particularly for high-risk and underserved populations. More...

Early detection and management are essential but often hindered by limited access to diagnostic technologies and specialist care. Addressing these gaps requires scalable solutions that integrate early screening, timely referrals, and proactive management to reduce complications and healthcare costs.

Siemens Healthineers (Forchheim, Germany) has entered into a strategic agreement with Carna Health (Boston, MA, USA) to accelerate the adoption of Carna’s artificial intelligence (AI)-enabled CKD platform and bring industry-leading point-of-care testing systems to emerging markets. The agreement aims to improve early detection and CKD management for high-risk and underserved populations by integrating Carna’s digital platforms with Siemens’ global diagnostics infrastructure.

It also aims to simplify CKD workflow processes, creating better pathways for referrals and providing timely nephrology care to improve patient outcomes while reducing healthcare costs for both patients and healthcare systems. Carna’s platform enables healthcare providers to identify and track CKD through AI-driven clinical decision support and community-based screening programs.

A population-based CKD screening program in Bermuda and Limbe, Cameroon, is currently enrolling 30,000 individuals across the Southwest and Littoral regions. The program combines Carna’s digital platform with point-of-care eGFR testing performed on the epoc Blood Analysis System from Siemens to bring scalable, tech-driven solutions and lifesaving care to communities that face challenges in accessing care.

Carna Health aims to enroll 25 million people in CKD screening programs worldwide by 2030, with plans to expand the platform to screen for other cardiometabolic diseases including diabetes. The focus is on accelerating U.S. deployment and expanding technological compatibility across diverse healthcare environments—from rural clinics to large health systems.

“We have a shared commitment to expanding digital and diagnostic testing innovation access in regions around the world where such technologies have historically been limited,” said Bethany Costello, head of Global Strategy for point of care diagnostics at Siemens Healthineers. “Combining forces will build more equitable kidney care pathways for patients globally.”

“This strategic agreement marks a turning point in the fight against CKD,” said Salvatore Viscomi, MD, Co-Founder and Chief Executive Officer of Carna Health. “By combining Carna’s AI-enabled platform with global diagnostics expertise from Siemens Healthineers, we’re delivering a unified approach to early identification, continuous monitoring, and proactive management of CKD. Together we can detect disease sooner, connect patients to care faster, and enable interventions that change health outcomes and save lives.”

Related Links:
Siemens Healthineers 
Carna Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
All-in-One Molecular System
AIO M160
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.